GILD · News · 20260815N

HIV and PrEP Demand Growth

GILEAD SCIENCES, INC. · 2026-08-15 · Importance 41 · Surprise 40

Gilead’s second-quarter revenue increased 10.6% year over year to $7.8 billion, according to the report. The HIV franchise and PrEP sales were identified as the primary growth drivers. The report also referenced continued positive commentary around Gilead’s distribution protection and HIV business momentum.

Key facts

• Gilead Sciences' Q2 revenue growth was driven by its HIV franchise and PrEP sales. source